Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Imatinib: Novel treatment of immune-mediated kidney injury
Eric Wallace,
Leslie Gewin
Division of Nephrology
Division of Veterans Affairs
Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
DBBS - Molecular Cell Biology
Institute of Clinical and Translational Sciences (ICTS)
Research output
:
Contribution to journal
›
Short survey
›
peer-review
19
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Imatinib: Novel treatment of immune-mediated kidney injury'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Novel Treatments
100%
Imatinib
100%
Immune Response
100%
Autoimmune Disease
100%
Kidney Injury
100%
Tyrosine Kinase Inhibitor
100%
Adverse Events
50%
Kidney
50%
Treatment Duration
50%
Fibrogenesis
50%
Severe Adverse Events
50%
Oncology
50%
Autoimmune Disease Treatment
50%
Medicine and Dentistry
Autoimmune Disease
100%
Kidney Injury
100%
Imatinib
100%
Immunity
100%
Adverse Event
66%
Tyrosine-Kinase Inhibitor
66%
Immune Response
33%
Fibrogenesis
33%
Oncology
33%
Pharmacology, Toxicology and Pharmaceutical Science
Imatinib
100%
Autoimmune Disease
100%
Kidney Injury
100%
Adverse Event
66%
Protein Tyrosine Kinase Inhibitor
66%